• Bertold Renner, Josef Zacher, Asokumar Buvanendran, Gerrit Walter, Jochen Strauss, and Kay Brune.
• Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nuremberg, Krankenhausstr. 9, 91054 Erlangen, Germany. renner@pharmakologie.uni-erlangen.de
• Naunyn Schmiedebergs Arch. Pharmacol. 2010 Feb 1; 381 (2): 127-36.

AbstractThe perioperative administration of selective cyclooxygenase-2 (COX-2)-inhibitors to avoid postoperative pain is an attractive option: they show favorable gastro-intestinal tolerability, lack inhibition of blood coagulation, and carry a low risk of asthmatic attacks. The purpose of this study was to determine the cerebrospinal fluid (CSF), plasma, and tissue pharmacokinetics of orally administered etoricoxib and to compare it with effect data, i.e., COX-2-inhibition in patients after hip surgery. The study was performed in a blinded, randomized, parallel group design. A total of 12 adult patients were included who received 120 mg etoricoxib (n = 8) or placebo (n = 4) on day 1 post-surgery. Samples from plasma, CSF, and tissue exudates were collected over a period of 24 h post-dosing and analyzed for etoricoxib and prostaglandin E(2) (PGE(2)) using liquid chromatography-tandem mass spectrometry and immuno-assay techniques. CSF area under the curve (AUC) [AUCs((O-24h))] for etoricoxib amounted to about 5% of the total AUC in plasma (range: 2-7%). Individual CSF lag times with respect to (50%) peak plasma concentration were

30 keywords...

hide…